NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
Clinical Trials
9 trialsNCT06341647 2025-01-24
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
GC Cell Corporation
Phase 1 Withdrawn
NCT05043987 2023-09-07
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Conjupro Biotherapeutics, Inc.
Phase 1 Withdrawn
NCT03682744 2022-04-06
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT03644459 2020-03-11
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
Lynkcell Inc.
Phase 1 Withdrawn
NCT02567396 2017-04-24
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT00017537 2013-08-05
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT00025532 2012-09-14
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT00429078 2012-03-02
Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer
Roger Williams Medical Center
Phase 1 Withdrawn